ChemoCentryx, Inc. (NASDAQ:CCXI) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
ChemoCentryx, Inc. (NASDAQ:CCXI) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02, Bloomberg Earnings reports. The firm had revenue of $8.94 million for the quarter.
ChemoCentryx (NASDAQ CCXI) traded down 5.61% during trading on Thursday, hitting $7.41. 403,608 shares of the stock traded hands. ChemoCentryx has a 12 month low of $3.95 and a 12 month high of $10.80. The firm’s 50-day moving average is $9.63 and its 200-day moving average is $7.72. The stock’s market cap is $356.81 million.
In related news, insider Petrus Bekker sold 19,877 shares of the stock in a transaction on Monday, July 10th. The stock was sold at an average price of $9.30, for a total transaction of $184,856.10. Following the completion of the sale, the insider now directly owns 79,426 shares of the company’s stock, valued at $738,661.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 223,649 shares of company stock valued at $2,157,360. Corporate insiders own 26.80% of the company’s stock.
CCXI has been the subject of several recent research reports. Zacks Investment Research raised shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Monday, July 17th. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a report on Tuesday. Finally, BidaskClub lowered shares of ChemoCentryx from a “strong-buy” rating to a “buy” rating in a report on Thursday.
ChemoCentryx Company Profile
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.